Pfizer and Protalix Make Deal on Gaucher’s Treatment Tuesday, December 1, 10:59 AM ET
Pfizer (NYSE:PFE) and Protalix (AMEX:PLX) announced today they made an agreement to develop and market a Gaucher’s disease treatment.
Pfizer will pay $60 million upfront to gain worldwide licensing rights to the drug, although Protalix will maintain rights in its home country of Israel. Pfizer will also make milestone payments of up to $55 million.
The drug, Taliglucerase alfa, replaces enzymes that Gaucher’s disease has destroyed. The disease can cause liver and neurologic problems. The Food and Drug Administration has granted the drug orphan
Any ideas and opinions presented in all Market News Video clips are for informational and educational purposes
only, and do not reflect the opinions of BNK Invest, Inc. or any of its affiliates, subsidiaries or partners.
In no way should any content contained herein be interpreted to represent trading or investment advice.
None of the information contained herein constitutes a recommendation that any particular security, portfolio,
transaction, or investment strategy is suitable for any specific person. All viewers agree that under no
circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held
liable for any loss or damage caused by your reliance on information obtained. Read Full Disclaimer.
